Table 1.
Summary of patient clinical details
| Case | Age (years), and sex | Disease duration (years) | Diagnosis and predominant symptoms | Surgical centre | Motor UPDRS ON/OFF drugs pre-op | Motor UPDRS ON/OFF DBS post-op | Medication pre-op (daily dose) | Medication post-op (daily dose) | Stimulation parameters at the time of the studya | DBS parameters at 3 months post-op or latera | Contacts in STN on post-op MRI | Contacts used for analysis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63, M | 8 | Akinetic-rigid | Berlin | 9/17 | 6/18 | Levodopa, 600 mg | Levodopa, 400 mg | R: 0−, 2+, 3.5 V | R: 1−, 2.5 V | R: 0, 1, 2 | R23 |
| Pergolide, 1.1 mg | Rasagilin, 1 mg | L: 0−, 2+, 5 V | L: 1−, 3.8 V | L: 0, 1, 2 | L23 | |||||||
| Entacapon, 800 mg | ||||||||||||
| 2 | 79, M | 7 | Akinetic-rigid, tremor | Berlin | 7/30 | 14/30 | Levodopa, 325 mg | Levodopa, 600 mg | R: 0−, 2+, 2 V | R: 2−, 1 V | R: 0, 1 | R12 |
| Pramipexol, 2.1 mg | L: 0−, 2+, 3 V | L: 2−, 2.8 V | L: 0, 1 | |||||||||
| 3 | 73, F | 16 | ON-OFF motor fluctuations | Berlin | 8/35 | 12/32 | Levodopa, 600 mg | Levodopa, 200 mg | R: 0−, 2+, 4 V | R: 1−, 2.1 V | R: 0, 1 | R01 |
| Pergolide, 3.5 mg | Pergolide, 1.5 mg | L: 0−, 2+, 4 V | L: 1−, 1.5 V | L: 0, 1 | ||||||||
| Amantadin, 100 mg | ||||||||||||
| 4 | 53, F | 12 | Akinetic-rigid, prolonged OFF periods | Berlin | 18/27 | 12/27 | Levodopa, 400 mg | Levodopa, 1100 mg | R: 0−, 2+, 4.2 V | R: 2−, 2 V | R: 0, 1 | L23 |
| Pergolide, 4 mg | L: 0−, 2+, 4.2 V | L: 2−, 2 V | L: 0, 1 | |||||||||
| 5 | 42, M | 7 | Tremor dominant | London | 5/41 | 16/42 | Levodopa, 500 mg | Levodopa, 400 mg | R:0−, 2+, 3.5 V | R: 1−, 2.8 V | R: 0, 1 | R12 |
| Pergolide, 3 mg | Ropinirole, 12 mg | L: 0−, 2+, 3.5 V | L: 1−, 3.3 V | L: 1, 2 | ||||||||
| Amantadine, 200 mg | ||||||||||||
| 6 | 40, F | 4 | ON-OFF dyskinesia | London | 9/53 | 17/33 | Levodopa, 300 mg | Levodopa, 500 mg | R: 0−, 2+, 2 V | R: 0−, 1.7 V | R: 0, 1 | L23 |
| Ropinirole, 21 mg | Ropinirole, 10 mg | L: 0−, 2+, 3.5 V | L: 0−, 1.7 V | L: 1, 2 | ||||||||
| Entacapone, 600 mg | ||||||||||||
| 7 | 56, M | 15 | Akinetic-rigid | London | 31/51 | n.a. | Levodopa, 1750 mg | Levodopa, 1000 mg | R: 1+, 2−, 5 V | R: 1−, 3.4 V | R: 1, 2 | R23 |
| Pergolide, 6 mg | Ropinirole, 9 mg | L: 1+, 2−, 3 V | L: 1−, 3.4 V | L: 1, 2 | ||||||||
| Amantadine, 300 mg | Amantadine, 200 mg | |||||||||||
| 8 | 55, M | 7 | ON-OFF dyskinesia | London | 6/23 | 10/43 | Levodopa, 1200 mg | Levodopa, 250 mg | R: 0−, 2+, 3 V | R: 2−, 3 V | R: 1, 2 | R12 |
| Cabergoline, 6 mg | Rotigotine, 10 mg | L: 0−, 2+, 3.2 V | L: 2−, 2 V | L: 1, 2 | L12 | |||||||
| 9 | 63, M | 13 | ON-OFF dyskinesia | London | 13/48 | 26/53 | Levodopa, 1500 mg | Levodopa, 400 mg | R: 1−, 2+, 4 V | R: 0−, 3.5 V, 180 Hz | R: 0, 1 | R12 |
| L: 1−, 2+, 2.7 V | L: 1−, 4 V, 180 Hz | L: 1, 2 | ||||||||||
| 10 | 72, M | 20 | ON-OFF dyskinesia | Leuven | 30/61 | n.a. | Levodopa, 950 mg | Levodopa, 275 mg | R:0−, 2+, 3 V | R: 2−, 1.1 V | R: 1, 2c | R12 |
| Entacapone, 1200 mg | Entacapone, 600 mg | L:0−, 2+, 3 V | L: 2−, 1.4 V | L: 1, 2c | ||||||||
| 11 | 61, M | 15 | Akinetic-rigid, fluctuations, dyskinesia | Berlin | 17/25 | 14/17 | Levodopa, 450 mg | Levodopa, 500 mg | R: 0−, 2+, 4 V | R: 1−, 2.6 V | R: 0, 1, 2b | R23b |
| Cabergoline, 6 mg | Pramipexol, 2.1 mg | L: 0−, 2+, 4 V | L: 1−, 1.6 V | L: 0, 1, 2b | L01b | |||||||
| Pramipexol, 2.1 mg | R: 1−, 3 V, 90 μsb | |||||||||||
| Amantadine, 450 mg | L: 1−, 3.5 V, 90 μsb |
pre-op, Preoperative; post-op, postoperative; R, right; L, left.
aAll patients were stimulated with 130 Hz, 60 μs, if not indicated otherwise.
bContacts in GPi.
cContact localization confirmed by x-ray in stereotactic conditions and superimposition on preoperative MRI.